Anti-sex hormone-dependent neoplasm agents-induced bone loss / 中华内分泌代谢杂志

ABSTRACT

Chemotherapy can induce bone loss. It is especially severe and the incidence of estimated bone loss may be as high as almost 100% for cancer patients treated with anti-sex hormone agents because of inhibition and deficiency of estrogens and/or androgens with the inappropriate ratio of two hormones during and "after therapy. Anti-sex hormone-dependent neoplasm agents-induced bone loss, characterized by an increase of bone turnover rate, should be treated in the early stage in order to prevent it from deterioration and bone fractures. The etiology, mechanism and clinical management of anti-sex hormone-dependent neoplasm agents-induced bone loss are briefly discussed in this review.